A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas

BACKGROUND: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolim...

Full description

Saved in:
Bibliographic Details
Published in:Br J Cancer
Main Authors: Eroglu, Z, Tawbi, H A, Hu, J, Guan, M, Frankel, P H, Ruel, N H, Wilczynski, S, Christensen, S, Gandara, D R, Chow, W A
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2015
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4430716/
https://ncbi.nlm.nih.gov/pubmed/25897676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.126
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items